omalizumab   Click here for help

GtoPdb Ligand ID: 6890

Synonyms: IGE25 | olizumab | R03DX05 | RG-3648 | rhumab-E25 | Xolair®
Approved drug Immunopharmacology Ligand
omalizumab is an approved drug (FDA (2003), EMA (2005))
Compound class: Antibody
Comment: Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that omalizumab is clone e25 in patent US5994511 [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: omalizumab

Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
immunoglobulin heavy constant epsilon Primary target of this compound Hs Antibody Binding 7.6 – 8.2 pKd - 1,3
⤷ pKd 8.2 (Kd 6.98x10-9 M) [1]
Description: In vitro binding affinity
pKd 7.6 (Kd 2.6x10-8 M) [3]
Description: F(ab) apparent binding affinity of e25 measured by surface plasmon resonance